复星系大股东连年减持力诺药包：IPO前突击入股后上市次年开启减持计划现已套现逾半

Core Viewpoint - The Shanghai Composite Index has reached new highs, surpassing the 3700-point mark, while there is a notable increase in share reduction announcements from major shareholders of listed companies, indicating a potential divergence between market performance and shareholder sentiment [1] Group 1: Shareholder Reduction Activities - From August 1 to the present, there has been a significant rise in share reduction announcements among listed companies [1] - On August 7, Lino Pharmaceutical announced that major shareholders, including Fosun Weishi and its concerted party Fosun Weiying, plan to reduce their holdings by a total of 840.73 million shares, accounting for a combined 5% of the company's total equity [1] - Since the company's listing in November 2021, Fosun Weishi and Fosun Weiying have consistently reduced their shareholdings [1] Group 2: Historical Reduction Plans - In December 2022, the company disclosed a reduction plan where the two shareholders intended to reduce their holdings by up to 1,394.46 million shares, representing 6% of the total equity [1] - The latest reduction plan announced on November 13, 2024, indicates intentions to reduce holdings by up to 686.78 million shares, which would bring their total shareholding down to 3.54% if fully executed [1] Group 3: Company Performance and Financial Metrics - Lino Pharmaceutical's performance has deteriorated since its IPO, with operational metrics such as inventory turnover days worsening, indicating declining operational efficiency and potential inventory accumulation risks [1] - In 2023, the company's revenue increased to 947 million, but net profit significantly dropped by 43.49% to 66 million [1] - For 2024, revenue is projected to grow by 14.09% to 1,081 million, but net profit is expected to decline further [1]